All News

Glucocorticoids-free zone in SLE?

Save

Nov 12, 2023

For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. They are a valuable 'friend' if used wisely, and can become a 'foe' if used excessively.

Read Article

Late Should Not Be Less (11.3.2023)

Save

Jack Cush, MD

Nov 03, 2023

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.

Read Article

H. Zoster Subunit Vaccine Efficacy with JAK Inhibitor Therapy

Save

Jack Cush, MD

Nov 02, 2023

JAK inhibitors are known to increase the risk of herpes zoster infections between between 3-5 fold. Two recent reports suggest variable efficacy when JAK inhibitor (JAKi) treated patients are vaccinated with the recombinant herpes zoster subunit vaccine (RZV).

Read Article

Oral Surveillance Study Alters Practice at VA

Save

Jack Cush, MD

Nov 02, 2023

Safety risks found in a postmarketing trial with the Janus-associated kinase (JAK) inhibitor tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for rheumatoid arthritis (RA) patients in the Veterans Affairs (VA) health system, researchers found.

Read Article

Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitor Treatment of Skin Disorders

Save

Jack Cush, MD

Nov 01, 2023

A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the placebo

Read Article

Tofacitinib efficacy and safety in axSpA pts by baseline CRP levels Elevated CRP pts with higher response in ASAS20, ASAS40, BASDAI50, etc. AE trended higher in normal CRP pts taking Tofa compared to placebo @RheumNow #ACR23 Abs#0518 https://t.co/nbiD36x1Pa

Robert B Chao, MD ( View Tweet)

Nov 12, 2023

Deucravacitinib (TYK2) data has been surprisngly good in SLE Strong rationale in PsA as well; I liked this poster & the focus on pain scores / patient QOL Probably my #1 draft pick for "drugs I'm buying right now" @RheumNow #ACR23 Abstr0508 https://t.co/FHNvgUrYxp

Mike Putman EBRheum ( View Tweet)

Nov 12, 2023

Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Brepocitinib ➡️ Tyk-2 inhibitor: IL12/23 & type I IFN ➡️ Phase Ib, 218 pts, 8% TNFi failure ➡️ 71% on concurrent MTX ➡️ Wk 16: ACR 50/70 & PASI75/90 improved, maintained through week 52 #ACR23 @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Nov 12, 2023

I’m not TYK’ed! Another TYK2 #TAK-279 in #PsA RCT. Yup it works in ballpark of other PsA #Rx. #PASI75 45.7%. No obvious dose response w 15 and 30 mg daily but more #acne at higher dose. #ACR23 @ACRheum @RheumNow poster L12 Where to use vs #Deucravitinib? Too early to say as Ph2 https://t.co/nMkgOlUf6s

Janet Pope ( View Tweet)

Nov 12, 2023

Nice VA study evaluating risk of lung cancer w/respect to RA treatment strategies Take home? No association. Aside from the (small risk) w/JAKi's, I think malignancy risks have been mostly overblown @NamrataRheum @RheumNow ABST0453 #ACR23 https://t.co/lDz0nV1KHt

Mike Putman EBRheum ( View Tweet)

Nov 12, 2023

Patient reported outcomes between clinic visits: worth doing? RA pts starting ADA/UPA, n=150 ArthritisPower/PatientSpot app for PROs between visits 52% of CDAI change explained by PROs Maybe a helpful tool in prioritising RA clinic reviews? @RADoctor #ACR23 ABST0380 @RheumNow https://t.co/oTttAlIxQR

David Liew drdavidliew ( View Tweet)

Nov 12, 2023

Who knew? VEXAS =cluster of findings from a somatic mutation N=110 studying retention of advanced Rx. #JAKi had far better retention than other #Rx. Although there could be channeling bias, I am impressed! Access for off label is a different issue #L03 #ACR23 @RheumNow @ACRheum https://t.co/RE4BVdZeWt

Janet Pope ( View Tweet)

Nov 12, 2023

In bDMARD-IR AS patients, UPA led to numerically greater improvements vs PBO in physical activity as measured by a wearable device over 14 wks, especially in sedentary patients. #ACR23 Abs #0530 https://t.co/6Me2XctK6D @rheumnow https://t.co/c6E2GfAGt4

Dr. Rachel Tate ( View Tweet)

Nov 12, 2023